Local websites
Businesses
Other websites
General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

More information

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

More information

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

More information

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

 

Oncology

Our oncology portfolio provides cancer patients with a broad range of therapies and practical solutions for the treatment of cancer and hematology. These include:

  • Afinitor (everolimus)
  • Exjade (deferasirox)
  • Femara (letrozole)
  • Gleevec/Glivec (imatinib mesylate/imatinib)
  • Sandostatin LAR (octreotide/IM injection)
  • Tasigna (nilotinib)
  • Zometa (zoledronic acid)

Visit the Novartis Oncology Websites:

Top links
Top downloads
Annual report 2012

Annual report 2012 >